Atara Biotherapeutics, Inc.
NASDAQ:ATRABiotechnology
+$0.19 today
- Market cap
- $68.98M
- Beta
- 0.11
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.67
Volume 0.02M
Average 1.40M
ATRA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Atara Biotherapeutics, Inc.NASDAQ: ATRA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $164K fell 99.4% year over year, behind the -92.4% change in trailing-twelve-month research & development. Over 3 fiscal years it compounded at -48.4% a year.
Context
- Research & development amounted to 31.0% of revenue in FY2025, down 86.5 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -99.4% toward the trailing-twelve-month pace of -92.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 37.45M USD
- Year-over-year change
- -75.3%
- 4-year CAGR
- -39.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.45M | -75.3% |
| FY2024 | 2024-12-31 | 151.48M | -32.6% |
| FY2023 | 2023-12-31 | 224.79M | -17.5% |
| FY2022 | 2022-12-31 | 272.53M | -3.4% |
| FY2021 | 2021-12-31 | 282M | — |
Research & Development vs competitors
How ATRA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -92.4% is the lowest of 11, against a peer median of -18.9%.
- Research & development amounts to 44.0% of revenue for ATRA, versus a peer median of 2026.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.68B USD | +26273.1% | +50.2% | 46313.4% | |
| LTM Mar 2026 | $151.37M USD | -38.7% | +6.7% | 152.0% | |
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $36.3M USD | -40.4% | -24.8% | 3629.9% | |
| LTM Mar 2026 | $35.41M USD | +46.4% | +65.0% | — | |
| LTM Mar 2026 | $30.07M USD | -8.9% | +1.3% | 422.2% | |
| LTM Mar 2026 | €22.87M EUR | -34.8% | -11.8% | 77989.1% | |
| LTM Mar 2026 | $12.86M USD | -17.9% | -24.0% | 9596.3% | |
| LTM Mar 2026 | $10.18M USD | -92.4% | -48.4% | 44.0% | |
| LTM Jan 2026 | $8.93M USD | +29.2% | -10.0% | 15.4% | |
| LTM Mar 2026 | $5.77M USD | -21.5% | -38.7% | — | |
| Peer median (excluding ATRA) | — | -18.9% | -10.9% | 2026.1% | |
Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 20.34M | 63.57M | 8.57M | 128.94M | 120.77M |
| Cost of Revenue | 282M | 269.99M | 8.89M | 21.01M | 21.21M |
| Gross Profit | (261.66M) | (206.42M) | (313K) | 107.93M | 99.56M |
| Gross Margin | -1286.4% | -324.7% | -3.7% | 83.7% | 82.4% |
| Research & Development | 282M | 272.53M | 224.79M | 151.48M | 37.45M |
| Selling, General & Admin | 78.8M | 68.13M | 50.91M | 39.89M | 26.25M |
| Operating Expenses | 78.8M | 74.1M | 275.69M | 191.37M | 63.7M |
| Depreciation & Amortization | 9.35M | 5.65M | 4.83M | 5.05M | 2.12M |
| EBITDA | (330.75M) | (222.26M) | (266M) | (75.75M) | 38.63M |
| EBITDA Margin | -1626.1% | -349.6% | -3102.7% | -58.7% | 32.0% |
| Operating Income | (340.46M) | (280.51M) | (276.01M) | (83.44M) | 35.86M |
| Operating Margin | -1673.9% | -441.2% | -3219.5% | -64.7% | 29.7% |
| Interest Income | 367K | 3.06M | 5.43M | 2.11M | 683K |
| Interest Expense | 0 | 373K | 5.29M | 4.62M | 3.79M |
| Other Income / Expenses | 367K | 52.22M | (105K) | (1.98M) | (3.14M) |
| Income Before Tax | (340.1M) | (228.29M) | (276.11M) | (85.42M) | 32.72M |
| Pre-Tax Margin | -1672.1% | -359.1% | -3220.7% | -66.2% | 27.1% |
| Income Tax Expense | 46K | 12K | 15K | (12K) | 31K |
| Net Income | (340.14M) | (228.3M) | (276.13M) | (85.4M) | 32.69M |
| Net Margin | -1672.3% | -359.1% | -3220.9% | -66.2% | 27.1% |
| EPS (Basic) | (90.78) | (55.96) | (65.18) | (11.41) | 2.61 |
| EPS (Diluted) | (90.78) | (55.96) | (65.18) | (11.41) | 2.57 |
| Weighted Avg Shares | 3.75M | 4.08M | 4.24M | 7.49M | 12.54M |
| Weighted Avg Shares (Diluted) | 3.75M | 4.08M | 4.24M | 7.49M | 12.72M |
Atara Biotherapeutics, Inc.
NASDAQ:ATRA
Intrinsic Alpha fair value
Locked
Current Price
$6.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.